# Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics From Single Dose of Intramuscular (IM) and Subcutaneous (SC) Donepezil (GB-5001) Injections Versus Donepezil Oral Tablet (Aricept®) in Healthy Male Volunteers

> **NCT06127368** · PHASE1 · UNKNOWN · sponsor: **G2GBio, Inc.** · enrollment: 56 (estimated)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** GB-5001A
- **DRUG:** GB-5001D
- **DRUG:** Oral cohort

## Key facts

- **NCT ID:** NCT06127368
- **Lead sponsor:** G2GBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-03
- **Primary completion:** 2024-09-17
- **Final completion:** 2025-01-14
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2023-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06127368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06127368, "Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics From Single Dose of Intramuscular (IM) and Subcutaneous (SC) Donepezil (GB-5001) Injections Versus Donepezil Oral Tablet (Aricept®) in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06127368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*